ResMed adjusts index footprint, shares hold gains on NYSE and ASX

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 10:10.

ResMed Inc. (US7611521078) continues to trade actively on the NYSE and ASX, with the shares recently changing hands around the 200 dollar mark in New York and near 21 Australian dollars in Sydney, according to exchange data.MarketBeat quote overview The adjustment of the stock’s role in Russell growth benchmarks and a still constructive analyst consensus frame the current picture for the medical technology group.MarketScreener benchmark note

Index reshuffle and benchmark role

ResMed features in the current FTSE Russell annual index review, with MarketScreener reporting a removal of the NYSE ticker RMD from at least one Russell growth benchmark in June 2026.MarketScreener benchmark note The stock last closed at about 200.29 dollars in the U.S., leaving it roughly 16.9 percent below the average analyst target of 260.60 dollars cited by the same source.MarketScreener consensus data

On the ASX, the ResMed CDI under ticker RMD recently traded near 21.17 Australian dollars, which Pearler shows as a strong percentage gain versus a historical reference level, underlining the divergence between local-currency performance and U.S.-dollar based targets.Pearler ASX price snapshot The dual listing gives international investors an additional venue alongside the NYSE.

Analyst estimates after the last quarter

ResMed’s latest reported quarter was the third fiscal quarter of 2026, released on April 30, where the company posted earnings per share of 2.86 dollars, topping the consensus estimate of 2.79 dollars by 0.07 dollars per share, according to MarketBeat.MarketBeat earnings summary Revenue trends and margin development were a key focus for analysts given the company’s exposure to sleep and respiratory care demand.

MarketScreener data indicate that the average 12-month target price of around 260.60 dollars still implies double-digit percentage upside versus the latest U.S. close, with a majority of covering brokers maintaining Buy or Overweight ratings.MarketScreener consensus data KeyBanc, for example, recently adjusted its target to 266 dollars from 290 dollars while retaining an Overweight stance, signaling some caution on valuation but continued confidence in the business model.KeyBanc price-target update

How ResMed earns its money

ResMed generates its revenue with sleep and respiratory care products, including continuous positive airway pressure devices and cloud-connected ventilators that diagnose and treat sleep-disordered breathing and chronic obstructive pulmonary disease, as described in its company profile.MarketScreener company profile The group also monetizes software platforms for out-of-hospital care management, which broaden its recurring revenue base.

Where the shares trade today

The ResMed shares (US7611521078) last traded on the NYSE at approximately 200.29 U.S. dollars as of 2026-06-26, 21:59, while the CDIs on the ASX changed hands around 21.17 Australian dollars on 2026-06-29, 01:00, according to MarketScreener and Pearler.

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Numbers and estimates are based on sources cited and may change over time.